Delivery of caffeine through an inhalation route

Patent 7078016 Issued on July 18, 2006. Estimated Expiration Date:

November 21, 2022. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

3560607

Medicated vapor production method and apparatus
Patent #: 3949743
Issued on: 04/13/1976
Inventor: Shanbrom

Respiratory humidifier
Patent #: 3982095
Issued on: 09/21/1976
Inventor: Robinson

Device for evaporation and inhalation of volatile compounds and medications
Patent #: 4303083
Issued on: 12/01/1981
Inventor: Burruss, Jr.

Apparatus for admixing liquid anesthetics and respiratory gas
Patent #: 4484576
Issued on: 11/27/1984
Inventor: Albarda

Vapor inhalation device
Patent #: 4566451
Issued on: 01/28/1986
Inventor: Badewien

Vaporizing unit
Patent #: 4734560
Issued on: 03/29/1988
Inventor: Bowen

Dosing device to provide vaporized medicament to the lungs as a fine aerosol
Patent #: 4735217
Issued on: 04/05/1988
Inventor: Gerth , et al.

Vaporizing unit
Patent #: 4853517
Issued on: 08/01/1989
Inventor: Bowen , et al.

Method and apparatus for administering dehydrated liposomes by inhalation
Patent #: 4895719
Issued on: 01/23/1990
Inventor: Radhakrishnan, et al.

More ...

Inventor

Rabinowitz, Joshua D.

Assignee

Alexza Pharmaceuticals, Inc.

Application

No. 10302010 filed on 11/21/2002

US Classes:

424/45, Organic pressurized fluid424/46, Powder or dust containing128/200.14, LIQUID MEDICAMENT ATOMIZER OR SPRAYER128/200.24, RESPIRATORY METHOD OR DEVICE604/290, Method of applying or removing material to or from body424/728Containing or obtained from Panax or Acanthopanax (e.g., ginseng, etc.)

Examiners

Primary: Hartley, Michael G.
Assistant: Haghighatian, M.

Attorney, Agent or Firm

Foreign Patent References

0 358 114 EP 03/01/1990
0 606 486 EP 07/01/1994
1 080 720 EP 03/01/2001
903866 GB 08/01/1962
WO 91/07947 WO 06/01/1991
WO 94/09842 WO 05/01/1994
WO 96/00071 WO 01/01/1996
WO 96/09846 WO 04/01/1996
WO 96/13161 WO 05/01/1996
WO 96/13290 WO 05/01/1996
WO 96/13291 WO 05/01/1996
WO 96/13292 WO 05/01/1996
WO 96/30068 WO 10/01/1996
WO 97/27804 WO 08/01/1997
WO 98/22170 WO 05/01/1998
WO 98/31346 WO 07/01/1998
WO 98/36651 WO 08/01/1998
WO 99/16419 WO 04/01/1999
WO 99/64094 WO 12/01/1999
WO 00/00176 WO 01/01/2000
WO 00/00215 WO 01/01/2000
WO 00/27363 WO 05/01/2000
WO 00/29053 WO 05/01/2000
WO 00/47203 WO 09/01/2000
WO 00/64940 WO 11/01/2000
WO 00/66084 WO 11/01/2000
WO 00/66206 WO 11/01/2000
WO 00/76673 WO 12/01/2000
WO 01/05459 WO 01/01/2001
WO 01/13957 WO 03/01/2001
WO 01/41732 WO 06/01/2001
WO 01/80829 WO 11/01/2001
WO 02/24158 WO 03/01/2002

International Classes

A61K 9/12
A61K 9/72

Abstract

The present invention relates to the delivery of caffeine through an inhalation route. Specifically, it relates to aerosols containing caffeine that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of caffeine. In a method aspect of the present invention, caffeine is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of caffeine, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering caffeine through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of caffeine; and, b) a device that forms a caffeine containing aerosol from the composition, for inhalation by the mammal.

Other References

Office Action mailed Aug. 13, 2003 for U.S. application 10/153,313 filed May 21, 2002 “Delivery of Benzodiazepines through an Inhalation Route”.
Bennett, R.L. et al. (1981). “Patient-Controlled Analgesia: A New Concept of Postoperative Pain Relief,” Annual Surg. 195(6):700-705.
Carroll, M.E. et al. (1990), “Cocaine-base smoking in rhesus monkeys: reinforcing and physiological effects,” Psychopharmacology (Berl). 102:443-450.
Clark, A. and Byron, P. (1986). “Dependence of Pulmonary Absorption Kinetics on Aerosol Particle Size,” Z. Erkrank. 166:13-24.
Darquenne, C. et al. (1997). “Aerosol Dispersion in Human Lung: Comparison Between Numerical Simulations and Experiments for Bolus Tests,” American Physiological Society. 966-974.
Database WPI, Section CH, Week 198941, Derwent Publications Ltd., London, GB; AN 1989-297792 AP002230849 & JP 01 221313 (Nippon Create KK), Sep. 4, 1989, abstract.
Davies, C.N. et al. (May 1972). “Breathing of Half-Micron Aerosols,” Journal of Applied Physiology. 32(5):591-600.
Dershwitz, M., M.D., et al. (Sep. 2000). “Pharmacokinetics and Pharmacodynamics of Inhaled versus Intravenous Morphine in Healthy Volunteers,” Anesthesiology. 93(3): 619-628.
Finlay, W.H. (2001). “The Mechanics of Inhaled Pharmaceutical Aerosols”, Academic Press: San Diego Formula 2.39. pp. 3-14 (Table of Contents). pp. v-viii.
Gonda,I. (1991). “Particle Deposition in the Human Respiratory Tract,” Chapter 176, The Lung: Scientific Foundations. Crystal R.G. and West, J.B. (eds.), Raven Publishers, New York. pp. 2289-2294.
Hatsukami D, et al. (May 1990) “A method for delivery of precise doses of smoked cocaine-base to humans.” Pharmacology Biochemistry & Behavior. 36(1):1-7.
Heyder, J. et al. (1986). “Deposition of Particles in the Human Respiratory Tract in the Size Range 0.005-15 μm,” J. Aerosol Sci. 17(5):811-822.
Huizer, H., “Analytical studies on illicit heron. V. Efficacy of volatilization during heroin smoking.” Pharmaceutisch Weekblad Scientific Edition (1987). 9(4):203-211.
Hurt, R.D., MD and Robertson, C.R., PhD, (Oct. 1998). “Prying Open the Door to the Tobacco Industry's Secrets About Nicotine: The Minnesota Tobacco Trial,” JAMA 280(13):1173-1181.
Lichtman, A.H. et al. (1996). “Inhalation Exposure to Volatilized Opioids Produces Antinociception in Mice,” Journal of Pharmacology and Experimental Therapeutics. 279(1):69-76.
Martin, B.R. and Lue, L.P. (May/Jun. 1989). “Pyrolysis and Volatilization of Cocaine,” Journal of Analytical Toxicology 13:158-162.
Mattox, A.J. and Carroll, M.E., (1996). “Smoked heroin self-administration in rhesus monkeys,” Psychopharmacology, 125:195-201.
Meng, Y. et al. “Inhalation Studies With Drugs of Abuse, ” NIDA Research Monograph, (1997) 173:201-224.
Meng, Y., et al. (1999). “Pharmacological effects of methamphetamine and other stimulants via inhalation exposure,” Drug and Alcohol Dependence. 53:111-120.
Pankow, J.F. et al. (1997). “Conversion of Nicotine in Tobacco Smoke to Its Volatile and Available Free-Base Form Through the Action of Gaseous Ammonia,” Envron. Sci. Technol. 31:2428-2433.
Pankow, J. (Mar. 2000). ACS Conference-San Francisco-Mar. 26, 2000. Chemistry of Tobacco Smoke. pp. 1-8.
Seeman, J. et al. (1999). “The Form of Nicotine in Tobacco. Thermal Transfer of Nicotine and Nicotine Acid Salts to Nicotine in the Gas Phase,” J. Agric. Food Chem. 47(12):5133-5145.
Sekine, H. and Nakahara, Y. (1987). “Abuse of Smoking Methamphetamine Mixed with Tobacco: 1. Inhalation Efficiency and Pyrolysis Products of Methamhetamine,” Journal of Forensic Science 32(5):1271-1280.
Vapotronics, Inc. (1998) located at http://www.vapotronics.com.au/banner.htm., 11 pages, (visited on Jun. 5, 2000).
Vaughan, N.P. (1990). “The Generation of Monodisperse Fibres of Caffeine” J. Aerosol Sci. 21(3): 453-462.
Ward, M.E. MD, et al. (Dec. 1997). “Morphine Pharmacokinetics after Pulmonary Administration from a Novel Aerosol Delivery System,” Chinical Pharmacology & Therapeutics 62(6):596-609.
Wood, R.W. et al. (1996). “Generation of Stable Test Atmospheres of Cocaine Base and Its Pyrolyzate, Methylecgonidine, and Demonstration of Their Biological Activity.” Pharmacology Biochemistry & Behavior. 55(2):237-248.
Database WPI, Section CH, Week 198941, Derwent Publication Ltd., London, GB; AN 1989-297792, AP002230849 & JP 01 221313 (Nippon Create KK), Sep. 4, 1989, abstract.
Office Action mailed Dec. 4, 2003 for US Appl. No. 10/057,198 filed Oct. 26, 2001 “Method And Device For Delivering A Physiologically Active Compound”.
Office Action mailed Jan. 12, 2005 for U.S. Appl. No. 10/057,197 filed Oct. 26, 2001, “Aersol Generating Device And Method”.
Office Action mailed Jun. 3, 2004 for U.S. Appl. No. 10/057,197 filed Oct. 26, 2001, “Aersol Generating Device And Method”.
Office Action mailed Dec. 15, 2003 for U.S. Appl. No. 10/057,197 filed Oct. 26, 2001, “Aerosol Generating Device And Method”.
Office Action mailed Feb. 27, 2004 for U.S. Appl. No. 10/146,080 filed May 13, 2002, “Aersol Forming Device For Use In Inhalation Therapy”.
U.S. Appl. No. 10/057,197, filed Oct. 26, 2001, Wensley et al.
U.S. Appl. No. 10/057,198, filed Oct. 26, 2001, Lloyd et al.
U.S. Appl. No. 10/146,080, filed May 13, 2002, Hodges et al.
U.S. Appl. No. 10/146,086, filed May 13, 2002, Hale et al.
U.S. Appl. No. 10/146,088, filed May 13, 2002, Hale et al.
U.S. Appl. No. 10/280,315, filed Oct. 25, 2002, Shen.
U.S. Appl. No. 10/302,614, filed Nov. 21, 2002, Lu.
U.S. Appl. No. 10/322,227, filed Dec. 17, 2002, Novack et al.
U.S. Appl. No. 10/719,899, filed Nov. 20, 2003, Hale et al.
U.S. Appl. No. 10/792,239, filed Mar. 3, 2004, Hale et al.
U.S. Appl. No. 10/437,643, filed May 13, 2003, Rabinowitz et al.
U.S. Appl. No. 10/422,385, filed May 20, 2003, Cross et al.
U.S. Appl. No. 10/633,876, filed Aug. 4, 2003, Hale et al.
U.S. Appl. No. 10/633,877, filed Aug. 4, 2003, Hale et al.
U.S. Appl. No. 10/696,959, filed Oct. 30, 2003, Hodges et al.
U.S. Appl. No. 10/712, 365, filed Nov. 12, 2003, Every et al.
U.S. Appl. No. 10/718,982, filed Nov. 20, 2003, Hale et al.
U.S. Appl. No. 10/719,540, filed Nov. 20, 2003, Hale et al.
U.S. Appl. No. 10/719,763, filed Nov. 20, 2003, Hale et al.
U.S. Appl. No. 10/734, 902, filed Dec. 12, 2003, Zaffaroni et al.
U.S. Appl. No. 10/735,198, filed Dec. 12, 2003, Rabinowitz et al.
U.S. Appl. No. 10/735,199, filed Dec. 12, 2003, Rabinowitz et al.
U.S. Appl. No. 10/735,495, filed Dec. 12, 2003, Rabinowitz et al.
U.S. Appl. No. 10/735,496, filed Dec. 12, 2003, Rabinowitz et al.
U.S. Appl. No. 10/735,497, filed Dec. 12, 2003, Zaffaroni et al.
U.S. Appl. No. 10/749,535, filed Dec. 30, 2003, Rabinowitz et al.
U.S. Appl. No. 10/749,536, filed Dec. 30, 2003, Rabinowitz et al.
U.S. Appl. No. 10/749,537, filed Dec. 30, 2003, Zaffaroni et al.
U.S. Appl. No. 10/749,539, filed Dec. 30, 2003, Rabinowitz et al.
U.S. Appl. No. 10/749,783, filed Dec. 30, 2003, Zaffaroni et al.
U.S. Appl. No. 10/750,303, filed Dec. 30, 2003, Rabinowitz et al.
U.S. Appl. No. 10/766,149, filed Jan. 27, 2004, Rabinowitz et al.
U.S. Appl. No. 10/766,279, filed Jan. 27, 2004, Rabinowitz et al.
U.S. Appl. No. 10/766,566, filed Jan. 27, 2004, Zaffaroni et al.
U.S. Appl. No. 10/766,574, filed Jan. 27, 2004, Rabinowitz et al.
U.S. Appl. No. 10/766,634, filed Jan. 27, 2004, Rabinowitz et al.
U.S. Appl. No. 10/766,647, filed Jan. 27, 2004, Zaffaroni et al.
U.S. Appl. No. 10/767,115, filed Jan. 28, 2004, Rabinowitz et al.
U.S. Appl. No. 10/768,205, filed Jan. 29, 2004, Zaffaroni et al.
U.S. Appl. No. 10/768,220, filed Jan. 29, 2004, Rabinowitz et al.
U.S. Appl. No. 10/768,281, filed Jan. 29, 2004, Rabinowitz et al.
U.S. Appl. No. 10/768,293, filed Jan. 29, 2004, Rabinowitz et al.
U.S. Appl. No. 10/769,046, filed Jan. 30, 2004, Rabinowitz et al.
U.S. Appl. No. 10/769,051, filed Jan. 30, 2004, Rabinowitz et al.
U.S. Appl. No. 10/769,157, filed Jan. 29, 2004, Rabinowitz et al.
U.S. Appl. No. 10/769,197, filed Jan. 29, 2004, Rabinowitz et al.
U.S. Appl. No. 10/775,583, filed Feb. 9, 2004, Rabinowitz et al.
U.S. Appl. No. 10/775,586, filed Feb. 9, 2004, Rabinowitz et al.
U.S. Appl. No. 10/791,915, filed Feb. 3, 2004, Hale et al.
U.S. Appl. No. 10/792,001, filed Feb. 3, 2004, Rabinowitz et al.
U.S. Appl. No. 10/792,012, filed Feb. 3, 2004, Hale et al.
U.S. Appl. No. 10/792,013, filed Mar. 3, 2004, Rabinowitz et al.
U.S. Appl. No. 10/792,096, filed Mar. 3, 2004, Hale et al.
U.S. Appl. No. 10/813,721, filed Mar. 31, 2004, Zaffaroni et al.
U.S. Appl. No. 10/813,722, filed Mar. 31, 2004, Rabinowitz et al.
U.S. Appl. No. 10/814,690, filed Mar. 31, 2004, Zaffaroni et al.
U.S. Appl. No. 10/814,998, filed Mar. 31, 2004, Rabinowitz et al.
U.S. Appl. No. 10/815,527, filed Apr. 1, 2004, Zaffaroni et al.
U.S. Appl. No. 10/816,407, filed Apr. 1, 2004, Rabinowitz et al.
U.S. Appl. No. 10/816,492, filed Apr. 1, 2004, Zaffaroni et al.
U.S. Appl. No. 10/816,567, filed Apr. 1, 2004, Rabinowitz et al.
U.S. Appl. No. 10/850,895, filed May 20, 2004, Damani et al.
U.S. Appl. No. 10/851,018, filed May 20, 2004, Hale et al.
U.S. Appl. No. 10/851,429, filed May 20, 2004, Hale et al.
U.S. Appl. No. 10/851,432, filed May 20, 2004, Hale et al.
U.S. Appl. No. 10/851,883, filed May 20, 2004, Hale et al.
U.S. Appl. No. 10/861,554, filed Jun. 3, 2004, Cross et al.
U.S. Appl. No. 10/912,417, filed Aug. 4, 2004, Bennett et al.
U.S. Appl. No. 10/912,462, filed Aug. 4, 2004, Hale et al.
U.S. Appl. No. 10/917,720, filed Aug. 12, 2004, Hale et al.
U.S. Appl. No. 10/917,735, filed Aug. 12, 2004, Hale et al.
U.S. Appl. No. 10/996,114, filed Nov. 23, 2004, Rabinowitz et al.
U.S. Appl. No. 10/996,162, filed Nov. 23, 2004, Rabinowitz et al.